ESHAP
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. R-ESHAP consists of: # Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes # Etoposide, an epipodophyllotoxin topoisomerase inhibitor # Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes # High-dose Ara-C - cytarabine # Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. R-ESHAP consists of: Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes Etoposide, an epipodophyllotoxin topoisomerase inhibitor Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes High-dose Ara-C - cytarabine Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
Dosing regimen
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1294953504 under CC BY-SA 4.0; modifications have been made.